- Anti-AIDS agents. Part 36: 17-carboxylated steroids as potential anti-HIV agents
-
In our search for novel anti-HIV agents, seven 17-carboxylated steroid derivatives were synthesized and evaluated as potential anti-HIV agents. Compound 13 exhibited potent anti-HIV activity in acutely infected H9 lymphocytes with EC50 and therapeutic index values of 0.8 μM and 300, respectively.
- Xia, Peng,Yang, Zheng-Yu,Xia, Yi,Zheng, Yun-Qing,Cosentino, L.Mark,Lee, Kuo-Hsiung
-
-
Read Online
- A A- loses the carbon -3,5-dehiscences-androst-5-one -3,17-process for the preparation of acid
-
The invention provides a preparation method of A-nor-3, 5-cracking-androstane-5 -keto-3, 17-diacid. The preparation method comprises the following steps: (1), 3-carbonyl-4-androstene-17beta carboxylic acid is dissolved in alkaline water, and the temperature of the solution is controlled to be 20-40 DEG C; (2), an oxidizing agent which is an aqueous solution including sodium periodate and potassium permanganate is added, and reaction is performed continuously for 1-3 h after addition; (3), after sufficient reaction, cooling is performed by ice brine until the temperature is 0-5 DGE C, spin-filtering is performed, and a filter cake is washed by ice alkaline water at the temperature of 0-5 DEG C and spin-dried; and (4), a filtrate obtained from spin-filtering is acidized and spin-filtered, and a filter cake is washed until an eluate is neutral. According to the provided method, an organic solvent is not used, accordingly, the method is economic and environment-friendly, and aftertreatment is simple; reaction is performed under homogeneous phase condition, the reaction temperature and iodate separation temperature are lower, the product quality is good, the yield is high, the iodate recovery rate is high, and the cost is low. Therefore, a product with higher purity can be obtained at high yield and low cost with the method.
- -
-
Paragraph 0046-0049
(2017/03/08)
-
- Synthesis and bioactivity of new Finasteride conjugate
-
Finasteride is a synthetic 4-azasteroid compound that acts by inhibiting type II 5α-reductase, the enzyme that converts the androgen testosterone to 5α-dihydrotestosterone. It was approved by the US FDA for the treatment of benign prostatic hyperplasia and male pattern baldness. Here the acylation product of Finasteride C-18 amide N-polimod was synthesized by employing acylation reaction with polimod amide as a pivotal intermediate. The structure of the key intermediate and target molecule was confirmed by infrared spectrum, 1H NMR and 13C NMR spectra and mass spectrum, and the inhibition of the steroid 5α-reductase and the rats' benign prostatic hyperplasia by the new Finasteride conjugate and Finasteride was also determined. The inhibition of the Finasteride conjugate on 5α-reductase was stronger than that of Finasteride. Prostate hyperplasia of rats was reduced by Finasteride conjugate treatment similar to the Finasteride treatment. However, the Finasteride conjugate treated animals showed better viable condition than the Finasteride treated ones, suggesting the new compound may have improved toxicity profile than Finasteride.
- Shuang, Zhao,Jiazhen, Wu,Lijuan, Yang,Zhuo, Li,Dahai, Yu,Jinfeng, Li,Jing, Yu,Yongtao, Liang,En-Si, Wang,Xuexun, Fang
-
supporting information; experimental part
p. 3439 - 3442
(2011/07/07)
-
- PROCESS FOR THE PREPARATION OF 4-AZASTEROIDS
-
The invention relates to a process for the preparation of 4-steroids of the formula (I), R1 and R2 are independently selected from the group consisting of hydrogen, F, Cl, Br, I, C1-6-alkyl and C1-6-alkoxy, and R4 is selected from the group consisting of hydrogen, (N, N-di-C1-6-alkylamino)methyl, 2-(N,N-di-C1-6-alkylamino)ethyl, C1-6alkyl, C1-6-alkoxy, phenyl and benzyl, and Q7 represents a carbonyl oxygen atom or is R7-1 and R7-2, wherein one of R7-1 and R7-2 is hydrogen and the other is selected from the group consisting of hydrogen, F, Cl, Br, I, C1-6-alkyl and C1-6-alkoxy and R9 represents hydrogen or F, and Q11 represents a carbonyl oxygen atom or is R11-1 and R11-2, wherein one of R11-1 and R11-2 is hydrogen and the other is selected from the group consisting of hydrogen, cyano, cyano-C1-3-alkyl, acetoxy, COOH and COO-M+, wherein M+ is Na+, K+ or NH+4, and R16 is selected from the group consisting of hydrogen cyano, C1-3-alkyl, cyano-C1-3-alkyl, acetoxy, COOH and COO-M+, wherein M+ is Na+, K+ or NH+4, and COOR represents COOH or COO-M+, wherein M+ is Na+, K+ or NH+4. The three step process comprises (i) a haloform reaction of a 17-acetyl steroid converting the acetyl group into a -COOR group, (ii) subsequent ozonolysis of the A-ring and (iii) re-closure of the A-ring by reaction with an appropriate nitrogen compound of formula H2NR4 to afford a compound of formula (I) above.
- -
-
Page/Page column 14
(2008/06/13)
-
- METHOD FOR THE SELECTIVE PREPARATION OF 3-OXO-4-AZA-5A-ANDROSTANE COMPOUND
-
This invention relates to a method for selectively preparing the 3-oxo-4-aza-5¥á-androstane compound which is used as an intermediate of finasteride by heating 3-oxo-4-aza-5-androstene in a mixture of formic acid and an alkanediol in the presence of zinc.
- -
-
-
- Azasteroids: Structure-activity relationships for inhibition of 5α-reductase and of androgen receptor binding
-
A series of steroids, primarily 4-azasteroids, were prepared and tested in vitro as inhibitors of human and rat prostatic 5α-reductase and of binding of dihydrotestosterone to the rat androgen receptor. The primary structural modifications were changes of the A ring and of moieties attached at the C-17 position of the steroid nucleus. New A-ring modifications included 4-cyano-3-oxoΔ4 system in the carbocyclic series and 1α-CN, 1α-CH3, 1α,2α-CH2, 2β-F, 2-aza, 2-oxa, and A-homo changes in the 3-oxo-4-aza series. In addition, 4-azasteroids with a D-homo ring or methyl substitution at C-7 (α and β) or C-16 (α and β) were prepared. The majority of the C-17 substituents were prepared from reactive intermediates derived from the 17β-COOH. Enhanced 5α-reductase inhibition in both the human and rat enzyme assays is seen with 4-CN substitution on 3-oxo-Δ4 steroids and with a C-17 side chain incorporating a lipophilically substituted semipolar group on the 4-aza-3-oxo-5α-androstane nucleus. Fewer highly active compounds were found in the human enzyme assay than in the rat assay. Structural requirements for inhibition of the rat androgen receptor are much different from those for inhibition of the enzyme. The 17β-OH moiety enhances potency more than any other feature while introduction of double bonds at C-1 or C-5 in the azasteroid gives a small improvement. Azasteroids unsubstituted at the 4-position show greatly diminished receptor activity.
- Rasmusson,Reynolds,Steinberg,Walton,Patel,Liang,Cascieri,Cheung,Brooks,Berman
-
p. 2298 - 2315
(2007/10/02)
-